According to new research announced today, the fragile X syndrome (FXS) market across the USA and Germany is projected to ...

Building on more than two decades of research, a study by MIT neuroscientists at The Picower Institute for Learning and ...

A growth occurring in the next five years will be fuelled by the launch of two high-priced pipeline products providing ...

Building on more than two decades of research, a study by MIT neuroscientists at The Picower Institute for Learning and ...

MIT researchers suggests a potential molecular strategy for treating fragile X syndrome by enhancing NMDA subunit function.

MIT neuroscientists have made a breakthrough in treating fragile X syndrome by leveraging a novel neurotransmitter signaling ...

Plymouth Meeting’s Harmony Biosciences’ stock fell 10% on Wednesday after the FDA rejected the expansion of its insomnia drug ...

Research analysts at HC Wainwright issued their Q1 2026 earnings estimates for shares of Anavex Life Sciences in a research report issued on Tuesday, February 18th. HC Wainwright analyst R. Selvaraju ...

Mizuho lowered the firm’s price target on Harmony Biosciences (HRMY) to $42 from $52 and keeps an Outperform rating on the shares. The firm ...

The U.S. Food and Drug Administration has approved a new drug application for a tablet version of Evrysdi (risdiplam) for ...